(R)-N-(2-(8-(benzyloxy)-2-oxo-1,2-dihydroquinolin-5-yl)-2-hydroxyethyl)-5,6-diethyl-2,3-dihydro-1H-inden-2-aminium benzoate

Min.Order / FOB Price:Get Latest Price

1 Gram	Negotiable

1 Gram

Negotiable

Min.Order :1 Gram
Purity: 98%HPLC
Payment Terms : L/C,T/T

Keywords

Indacaterol 753498-24-7 Indacaterol 2(1H)-Quinolinone,5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-(phenylmethoxy)-, monobenzoate

Quick Details

Appearance:According to the COA
Application:For research use only. Not for diagnostic or human use.
PackAge:1-10g 100g 500g 1kg 10kg
ProductionCapacity:10|Kilogram|Month
Storage:Store in dry place. Avoid Moisture. Keep container tightly closed.
Transportation:To inquire

Superiority:

Guangdong Raffles PharmaTech Co., Ltd providing:CAS#1228780-72-0, the most competitive price, best quality. We can provide efficient services and the best packaging. Welcome inquiries and orders from all over the world. If you have more questions or need other pharmaceutical intermediates, pharmaceutical raw materials and organic catalyst, please feel free to contact us.

Headquartered in Shenzhen Pingshan National Biopharmaceutical Industry Base, Shenzhen Huaxian Pharmaceutical Technology Co., Ltd. is a national high-tech enterprise with internationally leading core technologies such as asymmetric catalysis, continuous flow reaction, AI-assisted route and process design, deeply involved in and supporting the development of innovative drugs worldwide. There is a high-end API GMP plant covering an area of 28,000 square metres. The services are diversified to meet the different needs of our customers.

Details:

Catalog No.	ID19
Product Name：	(R)-N-(2-(8-(benzyloxy)-2-oxo-1,2-dihydroquinolin-5-yl)-2-hydroxyethyl)-5,6-diethyl-2,3-dihydro-1H-inden-2-aminium benzoate
CAS No.：	753498-24-7
Purity：	Enterprise Standard
Functional use:	Indacaterol Intermediates
Price：	Please email to: sales1@rafflespt.com
Disclaimer: products under protection of valid patent are not offered to the countries where the parent law is in force. It’s of the buyer's responsibility to check the patent situation in target markets.